Alexander V. Lobanov

Alexander V. Lobanov

Auto-generated profile, based on publicly available information

Alexander V. Lobanov

Research Institute of General Pathology and Pathophysiology

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2018 in Toxins
Verified
Journal Article
Open access
PDF file
ISIrina Shelukhina
Irina Shelukhina
MZMaxim N. Zhmak
Maxim N. Zhmak
ALAlexander V. Lobanov
Alexander V. Lobanov
IIIgor Ivanov
Igor Ivanov
AGAlexandra I. Garifulina
Alexandra I. Garifulina
Yuri UtkinYuri Utkin
Yuri Utkin
Azemiopsin (Az), a linear peptide from the Azemiops feae viper venom, contains no disulfide bonds, is a high-affinity and selective inhibitor of nicotinic acetylcholine receptor (nAChR) of muscle type and may be considered as potentially applicable nondepolarizing muscle relaxant. In this study, we investigated its preclinical profile in regard to in vitro and in vivo efficacy, acute and chronic toxicity, pharmacokinetics, allergenic capacity, immunotoxicity and mutagenic potency. The peptide effectively inhibited (IC50 ~ 19 nM) calcium response of muscle nAChR evoked by 30 μM (EC100) acetylcholine but was less potent (IC50 ~ 3 μM) at α7 nAChR activated by 10 μM (EC50) acetylcholine and had a low affinity to α4β2 and α3-containing nAChR, as well as to GABAA or 5HT3 receptors. Its muscle relaxant effect was demonstrated at intramuscular injection to mice at doses of 30–300 µg/kg, 30 µg/kg being the initial effective dose and 90 µg/kg—the average effective dose. The maximal muscle relaxant effect of Az was achieved in 10 min after the administration and elimination half-life of Az in mice was calculated as 20–40 min. The longest period of Az action observed at a dose of 300 µg/kg was 55 min. The highest acute toxicity (LD50 510 μg/kg) was observed at intravenous injection of Az, at intramuscular or intraperitoneal administration it was less toxic. The peptide showed practically no immunotoxic, allergenic or mutagenic capacity. Overall, the results demonstrate that Az has good drug-like properties for the application as local muscle relaxant and in its parameters, is not inferior to the relaxants currently used. However, some Az modification might be effective to extend its narrow therapeutic window, a typical characteristic and a weak point of all nondepolarizing myorelaxants.

1 March 2017 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
OKOksana N. Khokhlova
Oksana N. Khokhlova
ETElena A. Tukhovskaya
Elena A. Tukhovskaya
IKIrina N. Kravchenko
Irina N. Kravchenko
ESElena S. Sadovnikova
Elena S. Sadovnikova
IPIrina A. Pakhomova
Irina A. Pakhomova
AMArkady Murashev
Arkady Murashev

26 April 2018 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
ASAlexander A. Sidyakin
Alexander A. Sidyakin
AKAnna Kaysheva
Anna Kaysheva
AKArthur Kopylov
Arthur Kopylov
ALAlexander V. Lobanov
Alexander V. Lobanov
SMSergei G. Morozov
Sergei G. Morozov

1 March 2015 in Physiology & Behavior
Verified
Journal Article
Closed access
Dmitry M. DavydovDmitry M. Davydov
Dmitry M. Davydov
ALA.V. Lobanov
A.V. Lobanov
SMS.G. Morozov
S.G. Morozov
IGI.E. Gribova
I.E. Gribova
AMArkady Murashev
Arkady Murashev

1 September 2016 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
GSG. A. Slashcheva
G. A. Slashcheva
VRVladimir Rykov
Vladimir Rykov
ALA. V. Lobanov
A. V. Lobanov
AMA. N. Murashev
A. N. Murashev
YKYu. A. Kim
Yu. A. Kim
YKYuri Korystov
Yuri Korystov

15 October 2019 in Patologiya krovoobrashcheniya i kardiokhirurgiya
Verified
Journal Article
Open access
PDF file
OGO. A. Grebenchikov
O. A. Grebenchikov
ALA. V. Lobanov
A. V. Lobanov
ESE. R. Shayhutdinova
E. R. Shayhutdinova
AKArtem Kuzovlev
Artem Kuzovlev
AEA. V. Ershov
A. V. Ershov
VLValery V. Likhvantsev
Valery V. Likhvantsev
Aim. To investigate the cardioprotective effect of lithium chloride in vivo on a rat model of myocardial infarction.Methods. Twelve male Sprague-Dawley rats were randomly divided into two groups of six, with both groups modelling cardiac ischaemia and subsequent reperfusion. At the start of reperfusion, 30 mg/kg of 4.2% lithium chloride solution was intravenously administered via a catheter to the test group and 0.5 ml/kg of saline solution was administered to the comparison group. A control group comprised sham-operated rats that were not injected with any drugs other than anaesthesia during making skin incision. At the end of each experiment, the total area of the risk zone and areas of the infarction zone and left ventricle were calculated for each animal using a double-staining technique with 2% methylene blue and 1% triphenyltetrazolium chloride. A further series of experiments using 15 male Sprague-Dawley rats (third group) was performed to assess the protein content of glycogen synthase-3β in myocardial tissue. The method was similar to that for the earlier experiments; however, at the end of the experiments, the hearts were removed and homogenised, following which the concentration of glycogen synthase-3β was determined using electrophoresis.Results. The group treated with lithium chloride showed a significant decrease in the area of the infarction zone compared with the group treated with saline. The difference in the indices between the two groups was >26% (p < 0.05).Conclusion. This study demonstrated that 30 mg/kg of 4.2% lithium chloride solution, administered at the onset of reperfusion, exerted a protective effect on cardiomyocytes in a rat model of myocardial infarction by reducing the area of the infarction zone compared with that in the control group. This effect was probably mediated by an almost two-fold increase in the content of the phosphorylated form of glycogen synthase-3β in the myocardium. Received 23 June 2019. Revised 6 August 2019. Accepted 7 August 2019. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: A.N. KuzovlevData collection and analysis: O.A. GrebenchikovStatistical analysis: A.V. ErshovDrafting the article: A.V. Lobanov, E.R. ShayhutdinovaCritical revision of the article: V.V. LikhvantsevAll authors approved final version to be published